Rib-X Pharmaceuticals Receives $20,000,000 New Financing Round

  • Feed Type
  • Date
    1/11/2011
  • Company Name
    Rib-X Pharmaceuticals
  • Mailing Address
    300 George Street New Haven, CT 06511
  • Company Description
    Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis.
  • Website
    http://www.rib-x.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    In early 2011, we will begin a Phase 2b delafloxacin study to validate new objective endpoints for a near-term Phase 3 study and will initiate a long-term preclinical safety study with radezolid to demonstrate its key points of differentiation. We also expect to nominate an initial development candidate with activity against multi-drug resistant Gram-negative bacteria from our R?-04 program in early 2011.
  • M&A Terms
  • Venture Investor
    Warburg Pincus
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.